As of June 21, 2025, Nymox Pharmaceutical Corp (NYMX) reports a Current Ratio of 0.69.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Nymox Pharmaceutical Corp's Current Ratio
Over recent years, Nymox Pharmaceutical Corp's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2022-12-31 | 0.69 |
| 2021-12-31 | 0.58 |
| 2020-12-31 | 2.13 |
| 2019-12-31 | 2.61 |
| 2018-12-31 | 7.50 |
This slight downward trend highlights how Nymox Pharmaceutical Corp manages its short-term assets and liabilities over time.
Comparing Nymox Pharmaceutical Corp's Current Ratio to Peers
To better understand Nymox Pharmaceutical Corp's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Nymox Pharmaceutical Corp (NYMX) | 0.69 |
| ESSA Pharma Inc (EPIX) | 38.79 |
| Sernova Corp (SVA.V) | 19.19 |
| Xenon Pharmaceuticals Inc (XENE) | 17.85 |
| Protara Therapeutics Inc (TARA) | 15.64 |
| Fusion Pharmaceuticals Inc (FUSN) | 15.01 |
Compared to its competitors, Nymox Pharmaceutical Corp's Current Ratio is among the lowest compared to peers, suggesting tighter liquidity management or potential short-term obligations concerns.